DMMR Solid Malignant Tumor clinical trials at UCSF

1 research study open to eligible people

A dmmr solid malignant tumor is a type of cancer with a specific genetic defect. UCSF is testing a new treatment that uses immunotherapy to target these tumors. The trial aims to understand the safety and early effects of this treatment.

Showing trials for

  • Beta-only IL-2 ImmunoTherapY Study

    open to eligible people ages 18 years and up

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    San Francisco, California and other locations

Last updated: